Patents by Inventor Machiyo Ishigaki

Machiyo Ishigaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds with anti-cancer activity
    Patent number: 8415357
    Abstract: Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: April 9, 2013
    Assignee: Canbas Co., Ltd.
    Inventors: Takumi Kawabe, Machiyo Ishigaki, Takuji Sato, Sayaka Yamamoto, Yoko Hasegawa
  • Compounds with anti-cancer activity
    Patent number: 8084454
    Abstract: Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: December 27, 2011
    Assignee: Canbas Co., Ltd.
    Inventors: Takumi Kawabe, Machiyo Ishigaki, Takuji Sato, Sayaka Yamamoto, Yoko Hasegawa
  • COMPOUNDS WITH ANTI-CANCER ACTIVITY
    Publication number: 20110092514
    Abstract: Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.
    Type: Application
    Filed: November 19, 2010
    Publication date: April 21, 2011
    Applicant: CanBas Co., Ltd.
    Inventors: TAKUMI KAWABE, Machiyo Ishigaki, Takuji Sato, Sayaka Yamamoto, Yoko Hasegawa
  • PEPTIDE COMPOUND AND USE THEREOF
    Publication number: 20100112089
    Abstract: The present invention provides a method for the prophylaxis or treatment of cancer in a mammal, comprising administering a therapeutically effective amount of CBP501, a prodrug thereof or a pharmaceutically acceptable salt thereof to the mammal, wherein CBP501, a prodrug thereof or a pharmaceutically acceptable salt thereof is administered simultaneously with or before administration of a nucleic acid damaging agent.
    Type: Application
    Filed: May 13, 2009
    Publication date: May 6, 2010
    Inventors: Takumi Kawabe, Machiyo Ishigaki, Takuji Sato
  • Compounds with anti-cancer activity
    Publication number: 20080275057
    Abstract: Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.
    Type: Application
    Filed: April 11, 2008
    Publication date: November 6, 2008
    Applicant: CanBas Co., Ltd.
    Inventors: Takumi Kawabe, Machiyo Ishigaki, Takuji Sato, Sayaka Yamamoto, Yoko Hasegawa